Our Technology
Localized bioelectric modulation through SIHD-mediated ion-channel activation.
Localized delivery. Bioelectric modulation. Therapeutic impact.
01
SIHD Delivery
Injectable hydrogel forms at the target site for localized, sustained delivery.
02
Ion-Channel Activation
Ion channel activator molecules reprogram cancer cell signaling to suppress tumor progression.
03
Therapeutic Outcome
Designed to support tumor destabilization, treatment sensitivity, and reduced systemic exposure.
Localized delivery. Bioelectric Modulation. Therapeutic Impact
What
An injectable hydrogel platform for sustained, tumor-localized delivery of ion channel–targeting therapeutics.
How
SIHD establishes a localized drug depot that maximizes tumor exposure and minimizes systemic toxicity.
Why
Cancer therapies frequently fail because systemic dosing reaches toxicity before optimal tumor exposure. TheraStel is designed to overcome this fundamental limitation.
The Platform
Smart Injectable Hydrogel Delivery SIHD
SIHD is designed to form a localized drug depot after injection, allowing compounds to remain at the tumor site and release over time. This creates a new therapeutic logic: instead of chasing systemic exposure, TheraStel concentrates treatment directly in the tumor microenvironment.
Syringe-based
Designed for practical intertumoral or peritumoral administration.
Tumor-local exposure
Higher local concentration with lower systemic burden.
In situ depot
Forms locally to support sustained drug release.
Bioelectric Pharmocology
Engineered to reprogram cancer cell state, induce stress, and reduce tumor viability.